TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3046851

Group type: EXPERIMENTAL
Intervention: Cefodizime (CDZ) - 2 g daily dose i.v. for 6 days to patients and for 4 days to healthy subjects.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy subjects receiving CDZ at 0800 or 1800.
Number of subjects: 24
Study: 30304237

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (50 mg/kg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28734717

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice a day for 7 days)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No drug (standard of care)
Number of subjects: 74
Study: 26651470

Group type: EXPERIMENTAL
Intervention: Passive
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Both (passive + active)
Number of subjects: 492
Study: 23703407

Group type: EXPERIMENTAL
Intervention: Hypertonic saline combined with triamcinolone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal saline combined with triamcinolone
Number of subjects: 68
Study: 21990307

Group type: EXPERIMENTAL
Intervention: 2.0 g/d ginger
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18433023

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 16497273

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 12956319

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (0.4 g x d(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 12
Study: 11831450

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol, twice daily for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo, twice daily for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Formoterol vs. Placebo
Number of subjects: 19
Study: 9605722

Group type: EXPERIMENTAL
Intervention: Pseudoseizures
Number of subjects: 68

Group type: COMPARATOR
Intervention: Complex partial seizures
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Quality of Life in Epilepsy Inventory‐89
Number of subjects: 68
Study: 7847595

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3293733

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 15
Study: 31467052

Group type: EXPERIMENTAL
Intervention: New service delivery model including case management, counselling, AAC training, and AAC therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care provided to AAC users.
Number of subjects: 0
Study: 28335810

Group type: EXPERIMENTAL
Intervention: Errorless Learning (EL)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Trial and Error Learning (TEL)
Number of subjects: 161
Study: 26032132

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 69
Study: 23650701

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery plus small windows through canine fossa surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simple endoscopic surgery
Number of subjects: 50
Study: 21636796

Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 278

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 278
Study: 19567526

Group type: EXPERIMENTAL
Intervention: 5.5-h bedtime
Number of subjects: 11

Group type: COMPARATOR
Intervention: 8.5-h bedtime
Number of subjects: 11
Study: 16735016

Group type: EXPERIMENTAL
Intervention: Prototype mask (from Carburos Metálicos)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Profile Lite nasal mask (Respironics)
Number of subjects: 35

Group type: COMPARATOR
Intervention: ComfortClassic nasal mask (Respironics)
Number of subjects: 35
Study: 16279281

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 11309556

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9295896

Group type: EXPERIMENTAL
Intervention: Fraxiparine 3075 IU AXa (fixed dosage)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Fraxiparine 4100 or 6150 IU AXa (dosage adjusted for body weight)
Number of subjects: 150
Study: 8314476

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 3 million units subcutaneously, thrice weekly for 12 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 3 million units subcutaneously, for 6 months (after initial control period)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (12 months treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study: 31722130

Group type: EXPERIMENTAL
Intervention: SMS4BG text-message diabetes self-management support programme for 9 months
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual care for 9 months
Number of subjects: 366

Group type: COMPARATOR
Intervention: Comparison of intervention vs control
Number of subjects: 366
Study: 31477677

Group type: EXPERIMENTAL
Intervention: Buzzy®
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ShotBlocker®
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study: 28636674

Group type: EXPERIMENTAL
Intervention: Nutrition Behavior Change Communication (BCC) intervention
Number of subjects: 900
Study: 25925674

Group type: EXPERIMENTAL
Intervention: Colchicine (standard daily dose)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22946864

Group type: EXPERIMENTAL
Intervention: Multi-professional educational programme
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 22179917

Group type: EXPERIMENTAL
Intervention: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no prior preparation)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy (in postmenopausal women)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no prior preparation, in postmenopausal women)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 200 mcg Misoprostol sublingually, 2 hours before diagnostic hysteroscopy (in patients with a history of vaginal delivery)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no prior preparation, in patients with a history of vaginal delivery)
Number of subjects: 108
Study: 18640769

Group type: EXPERIMENTAL
Intervention: Nightly vardenafil
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: On-demand vardenafil
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study: 16646125

Group type: EXPERIMENTAL
Intervention: MTBI patients with PCS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Asymptomatic MTBI participants
Number of subjects: 26

Group type: COMPARATOR
Intervention: Matched normal control (NC) subjects
Number of subjects: 26
Study: 12514660

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 312
Study: 12858920

Group type: EXPERIMENTAL
Intervention: Rectal dihydroartemisinin (DATM)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 67
Study: 8807058

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) plus didanosine (group 1)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ZDV plus didanosine plus escalating doses (400 to 1,200 mg/day) of delavirdine (DLV) (group 2)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 1,200 mg of DLV alone per day (group 3)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ZDV plus 1,200 mg of DLV per day (group 4)
Number of subjects: 85
Study: 1737588

Group type: EXPERIMENTAL
Intervention: Patients from the EORTC trial 10801, which addresses breast conserving procedures.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls from the historical group (1960-1974).
Number of subjects: 0
Study: 6393814

Group type: EXPERIMENTAL
Intervention: Pirenzepine and antacids
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 66
Study: 30784637

Group type: EXPERIMENTAL
Intervention: Child development programme sessions (25 sessions)
Number of subjects: 1737

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1737
Study: 30384629

Group type: EXPERIMENTAL
Intervention: Gap-junction coupled neurons with increasing coupling strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurons with limited diversity (specific patterns removed)
Number of subjects: 0
Study: 27097646

Group type: EXPERIMENTAL
Intervention: Dance-based after-school intervention
Number of subjects: 31
Study: 25210016

Group type: EXPERIMENTAL
Intervention: Ipilimumab retreatment at 10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab induction at 0.3 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab induction at 3 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab induction at 10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab induction at 3 mg/kg (treatment-naive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab induction at 10 mg/kg (treatment-naive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab retreatment (0.3 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab retreatment (3 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipilimumab retreatment (10 mg/kg)
Number of subjects: 0
Study: 21544639

Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional segmental self‐stretching and breathing exercises (Control)
Number of subjects: 38
Study: 20854678

Group type: EXPERIMENTAL
Intervention: Self-assessment of HV using the Manchester scale
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Dichotomised Manchester scale scores
Number of subjects: 138
Study: 17229252

Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (other disease-modifying anti-rheumatic drug therapies)
Number of subjects: 32
Study: 15150139

Group type: EXPERIMENTAL
Intervention: Animated cartoons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Printed message about polio vaccinations
Number of subjects: 0
Study: 12237643

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 24
Study: 9850907

Group type: EXPERIMENTAL
Intervention: 1-piece PMMA IOL
Number of subjects: 70

Group type: COMPARATOR
Intervention: 3-piece silicone IOL
Number of subjects: 70
Study: 7989477

Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 2682980

Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 30188382

Group type: EXPERIMENTAL
Intervention: Tryptophan enhancement
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 164

Group type: COMPARATOR
Intervention: Sham day
Number of subjects: 164
Study: 27889574

Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension (BOS) 2 mg twice daily for 12 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 25925220

Group type: EXPERIMENTAL
Intervention: Baseline echocardiographic measures (LVEDV, LVEF, GLS) in patients treated with anthracyclines
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Baseline echocardiographic measures (GLS) in patients treated with anthracyclines
Number of subjects: 158
Study: 23909040

Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Essentale
Number of subjects: 100
Study: 20649445

Group type: EXPERIMENTAL
Intervention: Visualization of group members in a homogeneous way
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no visualization)
Number of subjects: 0
Study: 19306961

Group type: EXPERIMENTAL
Intervention: sTNF-R2 levels at enrollment (24-28 weeks gestation)
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: sTNF-R2 levels at weeks 24-28
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: sTNF-R2 levels in the highest quartile at week 24-28
Number of subjects: 986

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 986

Group type: COMPARATOR
Intervention: Aspirin group
Number of subjects: 986
Study: 16425094

Group type: EXPERIMENTAL
Intervention: Dedicated skin screening clinics (Group B)
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Centrally organised skin screening clinics (Group C)
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Skin screening within day‐to‐day primary care (Group A)
Number of subjects: 3110

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 3110
Study: 14641357

Group type: EXPERIMENTAL
Intervention: Mild soaps (8 different products)
Number of subjects: 0
Study: 10764435

Group type: EXPERIMENTAL
Intervention: NAC (cisplatin 50 mg/m², vincristine 1 mg/m² for 1 day, bleomycin 25 mg/m² for 3 days for three cycles followed by radical hysterectomy
Number of subjects: 124

Group type: COMPARATOR
Intervention: R/T (primary pelvic radiotherapy only)
Number of subjects: 124
Study: 8820790

Group type: EXPERIMENTAL
Intervention: Pathologists' agreement with index diagnosis (excluding minor discrepancies)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Major discrepancies in diagnoses
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Misdiagnosis of biopsy findings
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 16
Study: 1444609

Group type: COMPARATOR
Intervention: Mitomycin C (40 mg weekly for 8 weeks, with two additional instillations every 15 days in 50 ml saline)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (20 mg weekly for 8 weeks, with two additional instillations every 15 days in 50 ml saline)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 57
Study: 2932307

Group type: EXPERIMENTAL
Intervention: Cleocin T Topical 1 percent Solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cleocin T Topical 1 percent Lotion
Number of subjects: 0
Study: 31089709

Group type: EXPERIMENTAL
Intervention: High circulating microseminoprotein-beta (MSP) concentrations
Number of subjects: 1871

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) analysis
Number of subjects: 1871

Group type: EXPERIMENTAL
Intervention: Observational analysis from EPIC
Number of subjects: 1871
Study: 28663395

Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 75 mg of 0.25% levobupivacaine hydrochloride
Number of subjects: 264

Group type: COMPARATOR
Intervention: Periarticular infiltration with 150 mg of 0.25% levobupivacaine hydrochloride, 10 mg morphine sulphate, 30 mg ketorolac trometamol, 0.25 mg of adrenaline diluted with 0.9% saline to 150 ml
Number of subjects: 264
Study: 26330144

Group type: EXPERIMENTAL
Intervention: Whole-grain-enriched diet (WGDG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Refined grain diet (RDG)
Number of subjects: 27
Study: 23474642

Group type: EXPERIMENTAL
Intervention: tele‐SEGT (supportive‐expressive group therapy)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: tele‐CET (coping effectiveness training)
Number of subjects: 361

Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 361
Study: 21208082

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 15
Study: 19725253

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (150 mg per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17964975

Group type: EXPERIMENTAL
Intervention: Ibuprofen (7 mg/kg every 8 h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15094573

Group type: EXPERIMENTAL
Intervention: IV ketamine 1 mg/kg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: IV midazolam 0.15 mg/kg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: IV ketamine 1 mg/kg plus IV midazolam 0.1 mg/kg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: IV midazolam 0.1 mg/kg plus IV fentanyl 2 microg/kg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: IV propofol 2 mg/kg
Number of subjects: 126
Study: 11820726

Group type: EXPERIMENTAL
Intervention: Topical application of bovine pancreatic chymotrypsin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of papain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of bacterial protease from Bacillus licheniformis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of Alcalase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of Optimase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occluded application of aqueous enzyme solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-step unoccluded application of aqueous enzyme solution followed by commercial moisturizer
Number of subjects: 0
Study: 9428539

Group type: COMPARATOR
Intervention: Standard enteral formula (control group; n = 55)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Enriched enteral formula (n = 55)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN group; n = 56)
Number of subjects: 166
Study: 8002923

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 0
Study: 2681770

Group type: EXPERIMENTAL
Intervention: Dressings containing purified angiogenic and growth factors from human term placenta
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dressings not containing purified angiogenic and growth factors
Number of subjects: 18
Study: 4758487

Group type: EXPERIMENTAL
Intervention: Low nicotine cigarettes (<0.3 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High nicotine cigarettes (3.2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual brand cigarettes
Number of subjects: 10
Study: 31855493

Group type: EXPERIMENTAL
Intervention: Onion Peel Extract (OPE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30394960

Group type: EXPERIMENTAL
Intervention: Caregiver education (educational session for recognizing early symptoms/signs of heart failure, with recording in a diary of patient parameters)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Caregiver education
Number of subjects: 313

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 313
Study: 27710139

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 866
Study: 25847690

Group type: EXPERIMENTAL
Intervention: DM-1992 (extended-release carbidopa/levodopa), 2 times per day
Number of subjects: 34

Group type: COMPARATOR
Intervention: CD/L-dopa IR (immediate-release carbidopa/levodopa), 4.8 times per day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: DM-1992
Number of subjects: 34

Group type: COMPARATOR
Intervention: CD/L-dopa IR
Number of subjects: 34
Study: 23940575

Group type: EXPERIMENTAL
Intervention: Wheat-based whole grain foods
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Wheat + oats-based whole grain foods
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (refined diet)
Number of subjects: 206
Study: 21745038

Group type: EXPERIMENTAL
Intervention: High fat diet (HF; 40% energy from fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low fat plus n-3 FA diet (LFn3; 20% of energy from fat plus 3% of energy from n-3 FA)
Number of subjects: 0
Study: 19654956

Group type: EXPERIMENTAL
Intervention: Oral uridine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16740612

Group type: EXPERIMENTAL
Intervention: Low dietary sodium intake (10 mmol day(‐1)) for 5 days in Gly16 group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low dietary sodium intake (10 mmol day(‐1)) for 5 days in Arg16 group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Systemic administration of intravenous terbutaline (TRB)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Forearm blood flow (FBF) response to incremental doses of isoprenaline
Number of subjects: 32
Study: 15478443

Group type: EXPERIMENTAL
Intervention: Categories with a boundary coincident with the perceptual discontinuity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Categories defined such that the perceptual discontinuity fell within a category
Number of subjects: 0
Study: 11227395

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 to 20 mg/day
Number of subjects: 150

Group type: COMPARATOR
Intervention: Risperidone 4 to 12 mg/day
Number of subjects: 150
Study: 9024451

Group type: EXPERIMENTAL
Intervention: Prednisone (4 mg/kg per day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Nonsteroid treatment
Number of subjects: 141
Study: 8420726

Group type: EXPERIMENTAL
Intervention: Cimetidine (n = 65) as an iv infusion of 50 to 100 mg/hr
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cimetidine (n = 65)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Cimetidine (n = 56)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (n = 61)
Number of subjects: 131
Study: 6981177

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) intravenously for at least four days or orally for at least nine days (total daily dose, 10-20 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial intravenous therapy with doses of 15-20 mg/kg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 0